Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 293

Similar articles for PubMed (Select 16204394)

1.

Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.

Holdsworth MT, Vo-Nguyen T.

Ann Pharmacother. 2005 Nov;39(11):1903-10. Epub 2005 Oct 4. Review.

PMID:
16204394
2.
3.

Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.

Massaro AM, Lenz KL.

Ann Pharmacother. 2005 Jan;39(1):77-85. Epub 2004 Nov 23. Review.

PMID:
15562136
4.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
5.

Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.

Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, Lordick F.

Onkologie. 2009 Feb;32(1-2):30-4. doi: 10.1159/000183735. Epub 2009 Jan 20.

PMID:
19209016
6.
8.

Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.

Navari RM.

Drugs. 2009;69(5):515-33. doi: 10.2165/00003495-200969050-00002. Review.

PMID:
19368415
9.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27.

PMID:
19037667
10.
11.

Comparative activity of antiemetic drugs.

Jordan K, Schmoll HJ, Aapro MS.

Crit Rev Oncol Hematol. 2007 Feb;61(2):162-75. Review.

PMID:
17208005
12.

Acute and delayed nausea and emesis control in pediatric oncology patients.

Holdsworth MT, Raisch DW, Frost J.

Cancer. 2006 Feb 15;106(4):931-40.

13.
14.
15.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
17.

Antiemetic control: toward a new standard of care for emetogenic chemotherapy.

Navari RM.

Expert Opin Pharmacother. 2009 Mar;10(4):629-44. doi: 10.1517/14656560902731894 . Review.

PMID:
19284365
18.

Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.

Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F, Bianchini C, Perrone T.

Support Care Cancer. 2009 Feb;17(2):205-9. doi: 10.1007/s00520-008-0510-5. Epub 2008 Oct 7.

PMID:
18839220
19.

Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.

Liau CT, Chu NM, Liu HE, Deuson R, Lien J, Chen JS.

Support Care Cancer. 2005 May;13(5):277-86. Epub 2005 Mar 16.

PMID:
15770489
20.

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99-04 Palonosetron Study Group.

Cancer. 2003 Dec 1;98(11):2473-82.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk